Registered title, quoted from ClinicalTrials.gov
Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children
An open trial on glioma, registered on ClinicalTrials.gov. Led by Union Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07020052, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
3 years to 18 years; sex: all
Registered eligibility fields
Postmenopausal status, defined as a state of continuous cessation of menstruation for at least 12 months without other pathological or physiological reasons, and confirmed by serum follicle stimulating hormone (FSH) levels consistent with postmenopausal status.
Inclusion criterion 11
ANC≥1.5*10\^9/L;
Inclusion criterion 3
BIL<1.25 times the upper limit of normal (ULN);
Inclusion criterion 6
ALT and AST<2.5*ULN;
Inclusion criterion 7
Serum Cr ≤ ULN, endogenous creatinine clearance rate>50ml/min (Cockcroft Gaut formula); 9. Sign a written informed consent form before conducting any experimental activities; 10. Researchers determine that they are able to comply with the research protocol; 11. Negative pregnancy test (for female patients with fertility) during screening; 12. Male patients with fertility and female patients with fertility and pregnancy risk must agree to use two contraceptive methods throughout the study period (at least one of which is considered an effective contraceptive method).
Inclusion criterion 8
Previous or concurrent malignant tumors (excluding malignant tumors that have been cured and have a cancer free survival of more than 5 years, such as basal cell carcinoma of the skin, cervical carcinoma in situ, and papillary thyroid carcinoma);
Exclusion criterion 2
People with congenital or acquired immune deficiency (such as HIV infected people), active hepatitis B (HBV-DNA ≥ 104 copies/ml or 2000IU/ml) or hepatitis C (hepatitis C antibody is positive, and HCV-RNA is higher than the detection limit of the analytical method);
Exclusion criterion 5
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07020052, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
inclusion criteria 1.Age 3-18 years old, gender not limited; 2. Pathological diagnosis of diffuse midline gliomas in children;; 3. Not achieving complete surgical resection; 4. According to the 2021 WHO Classification of Central Nervous System Tumors (Fifth Edition) ; 5. Have not received specialized treatment for diffuse midline gliomas in children in the past;; 6. According to RECIST version 1.1 standard, at least one assessable target lesion is required; 7. ECOG physical fitness status is 0-4 points; 8. The main organ function is normal, which meets the following criteria:
- The standard for blood routine examination must meet the following criteria: (no blood transfusion within 14 days)
- Hb≥90g/L:
- ANC≥1.5*10\^9/L;
- PLT≥80*10\^9/L;
- Biochemical tests must meet the following standards
- BIL<1.25 times the upper limit of normal (ULN);
- ALT and AST<2.5*ULN;
- Serum Cr ≤ ULN, endogenous creatinine clearance rate>50ml/min (Cockcroft Gaut formula); 9. Sign a written informed consent form before conducting any experimental activities; 10. Researchers determine that they are able to comply with the research protocol; 11. Negative pregnancy test (for female patients with fertility) during screening; 12. Male patients with fertility and female patients with fertility and pregnancy risk must agree to use two contraceptive methods throughout the study period (at least one of which is considered an effective contraceptive method).
Female patients who do not have fertility (i.e. meet at least one of the following criteria):
- Have undergone hysterectomy and/or bilateral oophorectomy with documented records;
- medically confirmed ovarian dysfunction;
- Postmenopausal status, defined as a state of continuous cessation of menstruation for at least 12 months without other pathological or physiological reasons, and confirmed by serum follicle stimulating hormone (FSH) levels consistent with postmenopausal status.
A signed and dated informed consent form indicating that the patient (or legal representative, if permitted by local guidelines/practices) has been informed of all relevant aspects of the study.
- Patients who are willing and able to comply with visit arrangements, treatment plans, laboratory tests, and other research procedures.
exclusion criteria
- Previously received anti-tumor treatment for diffuse midline glioma;
- Previous or concurrent malignant tumors (excluding malignant tumors that have been cured and have a cancer free survival of more than 5 years, such as basal cell carcinoma of the skin, cervical carcinoma in situ, and papillary thyroid carcinoma);
- Uncontrolled clinical symptoms or diseases of the heart, such as: (1) NYHA grade II or above heart failure (2) unstable angina pectoris (3) myocardial infarction within 1 year (4) clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention in patients;
- Active infections that require treatment;
- People with congenital or acquired immune deficiency (such as HIV infected people), active hepatitis B (HBV-DNA ≥ 104 copies/ml or 2000IU/ml) or hepatitis C (hepatitis C antibody is positive, and HCV-RNA is higher than the detection limit of the analytical method);
- Known history of substance abuse, alcoholism, or drug use;
- According to the researcher's judgment, there may be other factors that could force the subject to terminate the study midway, such as suffering from other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors that may affect the subject's safety or the collection of trial data;
- Patients who the surgeon believes can undergo curative resection;
- Active pulmonary tuberculosis;
- Serious infections (including but not limited to hospitalization due to infection, bacteremia, or complications of severe pneumonia) that occurred within 4 weeks prior to the start of the study treatment.
Quoted from ClinicalTrials.gov, NCT07020052, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07020052, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.